Effectiveness of intensive follow-up after response in patients with small cell lung cancer

Lung Cancer

Volumn 59, Issue 2, 2008, Pages 255-261

  Sugiyama, Tomohide ^a   Hirose, Takashi ^a   Hosaka, Takamichi ^a   Kusumoto, Sojiro ^a   Nakashima, Masanao ^a   Yamaoka, Toshimitsu ^a   Okuda, Kentaro ^a   Ohmori, Tohru ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone scintigraphy; Computed tomography; Intensive follow up; Magnetic resonance; Recurrence; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE SCINTISCANNING; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MORBIDITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38649126178     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.016     Document Type: Article

References (26)

1. Seifter E.J., and Ihde D.C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 15 (1988) 278-299
2. Schiller J.H. Topotecan in small cell lung cancer. Semin Oncol 24 (1997) S27-S33
3. Chak L.Y., Daniels J.R., Sikic B.I., Torti F.M., Lockbaum P., and Carter S.K. Patterns of failure in small cell lung carcinoma of the lung. Cancer 50 (1982) 1857-1863
4. Albain K.S., Crowley J.J., Hutchins L., Gandara D., O'Bryan R.M., Von Hoff D.D., Griffin B., and Livingston R.B. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 72 (1993) 1184-1191
5. Kubota K., Nishiwaki Y., Kakinuma R., Hojo F., Matsumoto T., Ohmatsu H., Sekine I., Yokozaki M., Goto K., Ebi N., and Kodama T. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15 (1997) 292-296
6. Masuda N., Matsui K., Negoro S., Takifuji N., Takeda K., Yana T., Kobayashi M., Hirashima T., Kusunoki Y., Ushijima S., Kawase I., Tada T., Sawaguchi H., and Fukuoka M. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 (1998) 3329-3334
7. Kosmas C., Tsavaris N.B., Malamos N.A., Vadiaka M., and Koufos C. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 19 (2001) 119-126
8. Von Pawel J., Schiller J.H., Shepherd F.A., Fields S.X., Kleisbauer J.P., Chrysson N.G., Stewart D.J., Clark P.I., Palmer M.C., Depierre A., Carmichael J., Krebs J.B., Ross G., Lane S.R., and Gralla R. Topotecan versus cyclophsophamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
9. Hirose T., Horichi N., Ohmori T., Ogura K., Hosaka T., Ando K., Ishida H., Noguchi H., and Adachi M. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 40 (2003) 333-338
10. Smith T.J. Evidence-based follow-up of lung cancer patients. Semin Oncol 30 (2003) 361-368
11. Colice G.L., Rubins J., and Michael U. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest 123 (2003) 272S-283S
12. Perez E.A., Loprinzi C.L., Sloan J.A., Owens D.T., Novotny P.J., and Bonner J.A. Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma. Cancer 80 (1997) 676-680
13. Pujol J., Demoly P., Daures J., Tarhini H., Godard P., and Michel F.B. Chest tumor response measurement during lung cancer chemotherapy. Am Rev Respir Dis 148 (1992) 1149-1154
14. Libshitz H.I., and Sheppard D.G. Filling in of radiation therapy-induced bronchiectatic change. Radiology 210 (1999) 25-27
15. Chiu C.H., Chern M.S., Wu M.H., Hsu W.H., Wu Y.C., Huang M.H., and Chang S.C. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: preliminary report. J Thorac Cardiovasc Surg 125 (2003) 1300-1305
16. Yokoi K., Miyazawa N., and Arai T. Brain metastasis in resected lung cancer: value of intensive follow-up with computed tomography. Ann Thorac Surg 61 (1996) 546-551
17. Naunheim K.S., Virgo K.S., Coplin M.A., and Johnson F.E. Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 60 (1995) 1612-1616
18. Walsh G.L., O'Connor M., Willis K.M., Milas M., Wong R.S., Nesbitt J.C., Putnam J.B., Lee J., and Roth J.A. Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg 60 (1995) 1563-1572
19. Virgo K.S., McKirgan L.W., Caputo M.C., Mahurin D.M., Chao L.C., Caputo N.A., Naunheim K.S., Flye M.W., Gillespie K.N., and Johnson F.E. Post-treatment management options for patients with lung cancer. Ann Surg 222 (1995) 700-710
20. Gilbert S., ReidKR, Lam M.Y., and Petsikas D. Who should follow-up lung cancer patients after operation?. Ann Thorac Surg 69 (2000) 1696-1700
21. Westeel V., Choma D., Clement F., Woronoff-Lemsi M.C., Pugin J.F., Dubiez A., and Depierre A. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70 (2000) 1185-1190
22. Pieterman R.M., van Putten J.W., Meuzelaar J.J., Mooyaart E.L., Vaalburg W., Koeter G.H., Fidler V., Pruim J., and Groen H.J. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 (2000) 254-261
23. Inoue T., Kim E.E., Komaki R., Wong F.C., Bassa P., Wong W.H., Yang D.J., Endo K., and Podoloff D.A. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36 (1995) 788-793
24. Frank A., Lefkowitz D., Jaeger S., Gobar L., Sunderland J., Gupta N., Scott W., Mailliard J., Lynch H., and Bishop J. Decision logic for re-treatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32 (1995) 1495-1512
25. Bury T., Corhay J.L., Duysinx B., Daenen F., Ghaye B., Barthelemy N., Rigo P., and Bartsch P. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer. Eur Respir J 14 (1999) 1376-1380
26. Vansteenkiste J., Fischer B.M., Dooms C., and Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5 (2004) 531-540